Vericel Corporation: Advanced cell therapy; marketing MACI (cartilage repair) and Epicel (skin replacementt) in TAMs of $2b+. Q2 MACI and Epicel 2Q20 revs of $26.2m (vs $19m in 2018). 2019 revenue guidance for MACI® and Epicel® raised to $112 to $116m. Expanded MACI salesforce. Recently acquired US commercial rights for NexoBrid; BLA filing targeted for 1H 2020. .
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Marketed
Disease Space
Dermatology, Tools
Finance
Revenues
Industry
Biotechnology, Medical Device, Medical Technology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Cell Therapy
Website:
Profiles:
Address:
64 Sidney Street
Cambridge, MA 02139
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.